CAMBRIDGE, England--(BUSINESS WIRE)--AstraZeneca: Revenue and EPS summary FY 2025 % Change Q4 2025 % Change $m Actual CER1 $m Actual CER - Product Sales 55,573 9 9 14,538 9 7 - Alliance Revenue 3,067 39 38 959 34 33 Product Revenue2 58,640 10 10 15,497 10 8 Collaboration Revenue 99 (89) (89) 6 (99) (99) Total Revenue 58,739 9 8 15,503 4 2 Reported EPS ($) 6.60 45 43 1.50 55 47 Core3 EPS ($) 9.16 12 11 2.12 1 (2) Key performance elements for FY 2025 (Growth numbers at constant exchange rates.